NEW YORK (GenomeWeb) – Cowen said today that it has upgraded its rating on Hologic's shares to Outperform from Market Perform, based in part on the investment bank's expectation of "resilient" mid-single-digit or greater than high-single-digit revenue growth for Hologic's molecular diagnostics business.

In a research note, analyst Doug Schenkel said that Cowen's revenue growth expectations were also driven by expected sales for Hologic's new products, and continued mid-single-digit or high-single-digit growth for its surgical business.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.